{"id":"aceclidine-brimonidine-combination-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular hyperemia"},{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Allergic conjunctivitis"},{"rate":null,"effect":"Dry eye"}]},"_chembl":{"chemblId":"CHEMBL2062257","moleculeType":"Small molecule","molecularWeight":"442.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aceclidine is a direct-acting muscarinic agonist that enhances trabecular meshwork outflow facility. Brimonidine is an alpha-2 adrenergic agonist that reduces aqueous humor production and increases uveoscleral outflow. Together, these complementary mechanisms provide dual pathways for intraocular pressure reduction in glaucoma and ocular hypertension.","oneSentence":"This combination stimulates muscarinic receptors (via aceclidine) and alpha-2 adrenergic receptors (via brimonidine) to increase aqueous humor outflow and reduce intraocular pressure in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:00.927Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma or ocular hypertension (intraocular pressure reduction)"}]},"trialDetails":[{"nctId":"NCT05728944","phase":"PHASE3","title":"Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2023-03-06","conditions":"Presbyopia, Near Vision, Refractive Error","enrollment":229},{"nctId":"NCT05656027","phase":"PHASE3","title":"Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2022-12-19","conditions":"Presbyopia, Refractive Error, Eye Diseases","enrollment":469},{"nctId":"NCT06045299","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia","status":"COMPLETED","sponsor":"Corxel Pharmaceuticals","startDate":"2023-09-27","conditions":"Presbyopia, Near Vision, Miosis","enrollment":300},{"nctId":"NCT05753189","phase":"PHASE3","title":"Phase 3 Safety Study for the Treatment of Presbyopia Subjects","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2023-02-21","conditions":"Presbyopia, Near Vision, Miosis","enrollment":362},{"nctId":"NCT05431543","phase":"PHASE2","title":"Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2022-08-06","conditions":"Presbyopia, Refractive Errors, Eye Diseases","enrollment":59},{"nctId":"NCT05294328","phase":"PHASE2","title":"Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2022-05-05","conditions":"Presbyopia, Refractive Errors, Eye Diseases","enrollment":68},{"nctId":"NCT05936489","phase":"PHASE1","title":"Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2023-07-06","conditions":"Eye Diseases, Presbyopia, Refractive Errors","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LNZ101","Brimonidine and Aceclidine"],"phase":"phase_3","status":"active","brandName":"Aceclidine+Brimonidine combination ophthalmic solution","genericName":"Aceclidine+Brimonidine combination ophthalmic solution","companyName":"LENZ Therapeutics, Inc","companyId":"lenz-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination stimulates muscarinic receptors (via aceclidine) and alpha-2 adrenergic receptors (via brimonidine) to increase aqueous humor outflow and reduce intraocular pressure in the eye. Used for Glaucoma or ocular hypertension (intraocular pressure reduction).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}